01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

Open Orphan (ORPH) – Results of AGM October 2, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, announces that all the resolutions put to shareholders at the Annual General Meeting of the Company held earlier today were duly passed. Enquiries: Open Orphan plc Tel: +353 1 644 0007 Cathal Friel, Chief Executive Officer Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900 John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363 Anthony Farrell…

Continue reading

Open Orphan (ORPH) – CRUX Asset Management Ltd increase Holding(s) in Company October 1, 2019 – Posted in: Open Orphan (ORPH)

TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Open Orphan PLC 1b. Please indicate if the issuer is a non-UK issuer  (please mark with an “X” if appropriate) Non-UK issuer 2. Reason for the notification (please mark the appropriate…

Continue reading

Open Orphan #ORPH – Interim Results for 6 months ended 30 June 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focused, rare and orphan drug consulting services platform, announces its interim results for the six months ended 30 June 2019. Financial Highlights below (and in note 3 of the reported financial statements) reflect the interim results of Venn Life Sciences (“Venn”) prior to the reverse takeover by Open Orphan on the 28 June 2019. Reported results, based on IFRS accounting rules, reflect those of Open Orphan DAC while the Balance Sheet as of…

Continue reading

Open Orphan #ORPH presents at Total Market Solutions & Proactive Investors’ One2One Forum, London September 16, 2019 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that on Wednesday 18th September the Company will be attending and presenting at Total Market Solutions, Moorgate, at 12:30pm and will also be attending and presenting at Proactive Investors’ One2One Forum at Chesterfield Mayfair Hotel, London, W1J 5EB from 18:00 onwards. Cathal Friel, Open Orphan’s Chief Executive Officer, will be in attendance throughout both events and will be presenting to update existing and potential investors on the Company’s business plans for…

Continue reading

Open Orphan (ORPH) CEO Cathal Friel tells Alan Green why he expects 40 percent growth year on year September 9, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan (ORPH) CEO Cathal Friel tells Alan Green why he expects 40 percent growth year on year. Open Orphan (ORPH) currently trades on just 1x revenues & a market cap of just £15m. CEO Cathal Friel tells Alan Green why he expects to see his company, into which he’s invested £2m of his own cash, grow by some 40% year on year, reach a market cap of some £50m and pay a dividend to…

Continue reading

Open Orphan (ORPH) – Investor Event Attendance and Presentation – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending and presenting at the Shares Investor Evening at the Radisson Blu Hotel, Edinburgh, EH1 1TH at 17:20-21:30 on Thursday 12th September 2019. Cathal Friel, Open Orphan’s Chief Executive Officer, will be in attendance and will be presenting to update existing and potential investors on the Company’s business plans for 2019-2020. The event will provide an opportunity for investors to hear about…

Continue reading

Global Orphan Drugs Market Growth, Trends and Forecasts 2019-2024 – Business Wire August 19, 2019 – Posted in: Open Orphan (ORPH)

Article from BusinessWire.com The orphan drugs market is expected to register a CAGR of 11.5% over the forecast period Factors that are responsible for the growth of this market include market exclusivity for orphan drug developers, the rising prevalence of rare diseases, and favorable government policies. The market is expected to register an increased CAGR during the forecast period because the prevalence of rare diseases among the global population has been increasing in recent years.…

Continue reading